On Jul. 20, 2020, BioReference Laboratories, an OPKO Health company, announced accepted an Indefinite Delivery Indefinite Quantity contract award to provide Commercial Surge Capacity Testing for COVID-19 Emergency Response to the CDC.

BioReference will perform antibody testing to determine COVID-19 seroprevalence, and will provide results with key demographic information and analysis in collaboration with the CDC.